Answers are grounded in this paper and cite their sources.
Case report reveals mass spectrometry identifies daratumumab interference in an IgM myeloma patient, highlighting its role in preventing false diagnoses of clonal evolution.
BACKGROUND: Therapeutic monoclonal antibodies can interfere with immunofixation electrophoresis (IFE) during multiple myeloma monitoring. CASE PRESENTATION: Serum samples from an immunoglobulin M kappa (IgMκ) myeloma patient on daratumumab therapy were analyzed by serum protein electrophoresis (SPEP)/IFE and a mass spectrometry assay. A new immunoglobulin G kappa (IgGκ) band appeared on IFE during active treatment. Mass spectrometry identified a monoclonal peak at m/z 23,386, matching daratumumab. The band disappeared at trough concentration. CONCLUSIONS: Mass spectrometry rapidly identified daratumumab interference, serving as a reagent independent confirmatory tool to avoid misinterpreting therapeutic antibodies as clonal evolution.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: